Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. clinical trials

A subsidiary of Innovent Biologics, Inc.

The registry lists 7 studies whose lead sponsor is Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 14, 2026.

Status

Recruiting: 6
Active, not recruiting: 1

Phase

Phase 3: 6
Phase 2: 3
Phase 1: 1

Where

China: 7

Registry sponsor names on this page

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.7 studies

Something wrong with this grouping? Tell us on the Innovent Biologics, Inc. page.

Studies

Recruiting first, then most recently updated. Showing 7 of 7. All Innovent Biologics, Inc. studies →

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07643623Phase 2/3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsRecruitingNCT07589205Phase 1
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingNCT07490262Phase 2/3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
A Study of Picankibart in Patients With Active Psoriatic ArthritisRecruitingNCT07295509Phase 2/3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingNCT07377643Phase 3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT07265284Phase 3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyActive, not recruitingNCT06945107Phase 3
Sponsor listed in the registry: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.